Company intelligence / Profile preview
Shenzhen Immuno Cure Biomedical Co., Ltd.
- Ownership
- Private
- Development stage
- Phase 1
Overview
Shenzhen Immuno Cure Biomedical is a subsidiary of the Hong Kong-based Immuno Cure group. The company develops immunotherapies and DNA medicines targeting cancers, infectious diseases like HIV/AIDS and COVID‑19, and inflammatory conditions. Its lead program is a PD‑1-enhanced therapeutic HIV DNA vaccine that has completed Phase 1 in China. Other pipeline assets include preclinical cancer vaccines and antibody therapeutics. Two clinical trials are ongoing as of early 2025.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- DNA vaccinesMonoclonal antibodiesTherapeutic vaccinesAutologous CAR-T therapies
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Shenzhen Immuno Cure Biomedical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Immuno Cure Biomedical Co., Ltd..